The Research, Scholarship, and Artistic Achievement Awards nomination deadline has been extended to May 31, 2024. Click here for more information.

Mutated Non-Toxic E. coli Enterotoxins as Anti-Inflammatory Agents


Tulane University is actively seeking commercial entities to further develop and commercialize novel anti-inflammatory compounds derived from mutated non-toxic E. coli enterotoxins.


Treatment of several inflammatory diseases including but not limited to Irritable Bowel Disease (IBD)/ Colitis, Athsma, Dermatitis/Psoriasis, Rheumatoid and Psoriatic Arthritis, and Nephritis
Able to target a large family of inflammatory diseases depending on route of administration. Lower side-effects than current treatments of IBD which have chronic and short term side effects that can worsen the disease state. Can be administered orally, buccally, topically.

Current Work

This technology has been tested extensively in animal models of IBD and colitis. The discovered mechanism of action has indications in other inflammatory disease states.

Intellectual Property

Available For

Exclusive License in a Field
Non-exclusive License
Scientific Collaboration

For more information, please contact: